2023.Feb.02

OBI filed application for Phase II human clinical trial of first-in-class novel prodrug, OBI-3424, to TFDA

1.Date of occurrence of the event:2023/02/02 2.New drug name or code: first-in-class novel prodrug, OBI-3424 3.Indication: OBI-3424 is converted into a potently cytotoxic DNA alkylating agent specifically by the AKR1C3 enzyme, which is expressed by a variety of tumors leading to selective killing of those cells. Potential study subjects will have their tumor cells tested […]

HOMEWhat’s NewAnnouncementsOBI filed application for Phase II human clinical trial of first-in-class novel prodrug, OBI-3424, to TFDA

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2023.Jan.14

Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP505, has been granted by US FDA

2023.Feb.16

The first-in-class novel prodrug, OBI-3424, has been granted by TFDA to proceed to Phase II clinical trial